Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Xenon Pharmaceuticals Inc. clinical trials
The registry lists 23 studies whose lead sponsor is Xenon Pharmaceuticals Inc.. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 15, 2026.
Keep track of what changes. Save the Xenon Pharmaceuticals Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Xenon Pharmaceuticals Inc..
- Xenon Pharmaceuticals Inc.23 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 23 of 23.
- An Open-label Study of XEN1101 in EpilepsyEnrolling by invitationNCT05718817Phase 3
- A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)RecruitingNCT05716100Phase 3
- A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic SeizuresRecruitingNCT05667142Phase 3
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)Active, not recruitingNCT07076407Phase 3
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderActive, not recruitingNCT06775379Phase 3
- An Open-Label Study of Azetukalner in Major Depressive DisorderActive, not recruitingNCT06922110Phase 3
- An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)Active, not recruitingNCT07217860Phase 3
- A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)Active, not recruitingNCT07172516Phase 3
- A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive DisorderCompletedNCT05376150Phase 2
- A Randomized Study of XEN1101 Versus Placebo in Focal-Onset SeizuresCompletedNCT05614063Phase 3
- An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEETerminatedNCT04912856Phase 3
- A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal EpilepsyActive, not recruitingNCT03796962Phase 2
- XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic EncephalopathyTerminatedNCT04639310Phase 3
- Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101.CompletedNCT03340220Phase 1
- Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101CompletedNCT04952467Phase 1
- Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901CompletedNCT03467100Phase 1
- A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical GelCompletedNCT02656043Phase 1/2
- Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101CompletedNCT03468725Phase 1
- Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited ErythromelalgiaCompletedNCT01486446Phase 1/2
- A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)CompletedNCT01195636Phase 2
- Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth ExtractionCompletedNCT00954356Phase 2
- Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)CompletedNCT01090622Phase 1/2
- Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy VolunteersCompletedNCT00813670Phase 1